<DOC>
	<DOCNO>NCT00149214</DOCNO>
	<brief_summary>An open-label randomized Phase II study order explore two different sequential anthracycline-based neoadjuvant treatment regimen female patient primary , operable breast cancer ( T2-T4/N0-2/M0 ) .</brief_summary>
	<brief_title>Preoperative Treatment Breast Cancer With Two Different Sequential Treatment Regimens</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm diagnosis primary early breast cancer , tumor size great equal 2 centimeter ( cm ) , Stages T2T4/N02 . Performance status 02 Eastern Cooperative Oncology Group ( ECOG ) . Adequate organ function ( bone marrow , hepatic , renal , cardiac ) . Prior anthracyclines part prior anticancer therapy . Concurrent antitumor therapy . Second primary malignancy . Serious concomitant systemic disorder . Preexisting sensorial motor neuropathy Grade 1 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>